Neuroprotection in Traumatic Brain Injury: Mesenchymal Stromal Cells can Potentially Overcome Some Limitations of Previous Clinical Trials

被引：23

作者：

Carbonara, Marco ^{[1
]}

Fossi, Francesca ^{[2
,3
]}

Zoerle, Tommaso ^{[1
]}

Ortolano, Fabrizio ^{[1
]}

Moro, Federico ^{[2
]}

Pischiutta, Francesca ^{[2
]}

Zanier, Elisa R. ^{[2
]}

Stocchetti, Nino ^{[1
,4
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Anaesthesia & Crit Care, Neurosci Intens Care Unit, Milan, Italy

[2] Ist Ric Farmacol Mario Negri IRCCS, Dept Neurosci, Lab Acute Brain Injury & Therapeut Strategies, Milan, Italy

[3] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy

[4] Milan Univ, Dept Pathophysiol & Transplants, Milan, Italy

来源：

FRONTIERS IN NEUROLOGY | 2018年 / 9卷

关键词：

traumatic brain injury; mesenchymal stromal cells; brain protection; brain repair; vulnerability; SEVERE HEAD-INJURY; PLACEBO-CONTROLLED TRIAL; PROMOTES FUNCTIONAL RECOVERY; RANDOMIZED CONTROLLED-TRIAL; ENDOTHELIAL GROWTH-FACTOR; NMDA RECEPTOR ANTAGONIST; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; NEUROTROPHIC FACTORS; ADULT RATS;

D O I：

10.3389/fneur.2018.00885

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. In the last 30 years several neuroprotective agents, attenuating the downstream molecular and cellular damaging events triggered by TBI, have been extensively studied. Even though many drugs have shown promising results in the pre-clinical stage, all have failed in large clinical trials. Mesenchymal stromal cells (MSCs) may offer a promising new therapeutic intervention, with preclinical data showing protection of the injured brain. We selected three of the critical aspects identified as possible causes of clinical failure: the window of opportunity for drug administration, the double-edged contribution of mechanisms to damage and recovery, and the oft-neglected role of reparative mechanisms. For each aspect, we briefly summarized the limitations of previous trials and the potential advantages of a newer approach using MSCs.

引用

页数：9

共 115 条

[1] Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial [J].